CRANBURY, N.J., April 3, 2018 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a biopharmaceutical
company developing targeted, receptor-specific peptide therapeutics
for the treatment of diseases with significant unmet medical need
and commercial potential, today announced the presentation of a
poster on preclinical studies of an oral formulation of PL-8177, a
selective melanocortin receptor 1 (MC1r) agonist peptide. The
presentation was made at the 2018 Keystone Symposia on "The
Resolution of Inflammation in Health and Disease" held
March 24-28, 2018 at the Royal Dublin
Society, Dublin, Ireland.
PL-8177 is Palatin's lead clinical development candidate for
ulcerative colitis and other inflammatory bowel diseases.
The data demonstrates that the oral formulation of PL-8177 was
protected from degradation in the stomach and small intestine and
delivered to the large intestine and colon over an extended
period. In addition, orally administered PL-8177 had a
significant effect on resolving inflammation in a rat bowel
inflammation model. The poster can be found on the Palatin
website at
https://www.palatin.com/resources/corporate-presentation/poster-presentations/.
"The development of an orally administered capsule of PL-8177 is
a major step forward for our ulcerative colitis program," said
Carl Spana, Ph.D., CEO and President
of Palatin Technologies. "We are moving the oral formulation
into human pharmacokinetic studies, which we currently anticipate
beginning in the fourth quarter of 2018."
PL-8177 is the subject of a randomized, double-blind,
placebo-controlled, single and multiple ascending dose Phase 1
study intended to evaluate the safety and tolerability of systemic
exposure of PL-8177 administered via subcutaneous injection.
Subject dosing is ongoing with top line data currently expected in
the third quarter of 2018.
About PL-8177
PL-8177 is a synthetic cyclic heptapeptide with demonstrated
efficacy in animal inflammatory bowel disease models. Palatin
has developed an oral formulation of PL-8177 that has been
validated in animal studies, which is scheduled to be explored in
future clinical investigations. PL-8177 is a potent agonist
at the human MC1r, with sub-nanomolar affinity binding and
EC50 functional values.
About Ulcerative Colitis
Ulcerative colitis is a chronic disease of the large intestine
(colon), with inflammation and ulcerations that can cause
significant abdominal pain, persistent diarrhea, loss of appetite
and other symptoms. Over 700,000 individuals in the United States are affected by ulcerative
colitis, with over 350,000 diagnosed with moderate-to-severe
disease. Existing treatments are not effective in a large
portion of patients with moderate-to-severe ulcerative colitis,
with some severe cases resulting in surgical removal of the
colon.
About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company
developing targeted, receptor-specific peptide therapeutics for the
treatment of diseases with significant unmet medical need and
commercial potential. Palatin's strategy is to develop products and
then form marketing collaborations with industry leaders in order
to maximize their commercial potential. For additional information
regarding Palatin, please visit Palatin's website at
www.Palatin.com.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin
Technologies, Inc., such as statements about potential clinical
indications for PL-8177, clinical trial results with PL-8177,
potential actions by regulatory agencies including the FDA,
regulatory plans, development programs, proposed indications for
product candidates and market potential for product candidates, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and as that term is defined in the Private Securities
Litigation Reform Act of 1995. Palatin intends that such
forward-looking statements be subject to the safe harbors created
thereby. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that could cause Palatin's
actual results to be materially different from its historical
results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and the need for regulatory
approvals, Palatin's ability to fund development of its technology
and establish and successfully complete clinical trials, the length
of time and cost required to complete clinical trials and submit
applications for regulatory approvals, products developed by
competing pharmaceutical, biopharmaceutical and biotechnology
companies, commercial acceptance of Palatin's products, and other
factors discussed in Palatin's periodic filings with the Securities
and Exchange Commission. Palatin is not responsible for updating
for events that occur after the date of this press release.
View original content with
multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-presents-preclinical-oral-formulation-data-on-pl-8177-an-investigational-melanocortin-receptor-1-agonist-for-inflammatory-bowel-diseases-300623071.html
SOURCE Palatin Technologies, Inc.